AHA Coding Clinic® for HCPCS - 2020 Issue 4; For Your Information

New HCPCS Level II codes for monoclonal antibody therapies for COVID-19

The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for the investigational monoclonal antibody therapy, bamlanivimab, on November 9, 2020. On November 21, 2020, an EUA was issued for casirivimab and imdevimab (also known as REGN-COV2 or REGEN-COV2). Casirivimab and imdevimab are to be administered together. These monoclonal antibody therapies are for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization. The Centers for Medicare and Medicaid Services (CMS) has identified specific HCPCS Level II code(s) listed...

To read the full article, sign in and subscribe to the AHA Coding Clinic® for HCPCS.


The AHA Coding Clinic for HCPCS includes:

  • The official publication for Level I HCPCS (CPT-4 codes) for hospital providers
  • Also specific Level II HCPCS codes for hospitals, physicians and other health professionals
  • Current newsletters added each quarter
  • Full Archives back to 2001
  • Fully searchable through Find-A-Code's Comprehensive Search
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information page link back to related articles
  • View all the articles associated with any code, right from the code page!
Access to this feature is available in the following products:
  • AHA's Coding Clinic® - HCPCS +Archives

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.